$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
奥拉帕尼用于BRCA突变晚期卵巢癌一线治疗
2025-10-19 11:44:20
Check Details
尼拉帕尼延长了卵巢癌患者无进展生存期
2025-10-19 11:44:20
Check Details
FDA批准尼拉帕尼治疗复发性卵巢癌
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗老年卵巢癌患者效果?
2025-10-19 11:44:20
Check Details
尼拉帕尼降低卵巢癌死亡风险
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗卵巢癌安全有效
2025-10-19 11:44:20
Check Details
尼拉帕尼治疗BRCA突变患者优于安慰剂
2025-10-19 11:44:20
Check Details
索拉非尼联合化疗治疗复发性卵巢癌
2025-10-19 11:44:20
Check Details
尼拉帕尼延长卵巢癌患者无进展生存期
2025-10-19 11:44:20
Check Details
奥拉帕利治疗晚期卵巢癌
2025-10-19 11:44:20
Check Details
奥拉帕利获批用于铂敏感复发性卵巢癌
2025-10-19 11:44:20
Check Details
奥拉帕尼单药治疗BRCA突变晚期癌症
2025-10-19 11:44:20
Check Details
1
2
...
766
767
768
769
770
771
772
...
4157
4158
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
2
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
3
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
4
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
5
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
6
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
7
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)
8
Chemical Structure of Capivasertib: A Novel AKT Inhibitor
9
Capivasertib: An AKT Inhibitor for Breast and Prostate Cancer
10
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
11
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
12
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations